Tehran University of Medical Sciences The Research in Heart Yield and Translational Medicine (RHYTHM) 3115-7270 15 4 2020 10 31 199 201 Behshad Naghshtabrizi Associate Professor of Cardiology, Farshchian Heart Center, Hamadan University of Medical Sciences, Hamadan, Iran. Saeed Bashirian Associate Professor of Health Education, Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. Naghme Shirafkan Department of Immunology, Hamadan University of Medical Sciences, Hamadan, Iran. Nima Naghshtabrizi Assistant Professor of Cardiology, Cardiology Department Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Fereshteh Mehri Assistant Professor of Toxicology, Nutrition Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. 2020 07 06 2020 11 28 In  this letter we have focused on two important issues, possible risk of MI in patients who are infected with SARS- Cov-2 and different therapeutic protocols that are currently applying for management of them which may be harmful in this group of patients with heart disorders who are infected with SARS- Cov-2 patients and must be replaced with safer ones. So, Calcineurin inhibitor and cyclosporine are more likely to have less cardiac side effects in these patients. Finally, it should be considered that Calcineurin inhibitor and cyclosporine require extensive clinical trial for evaluation of their effects in patients with heart disorders who are infected with SARS- Cov-2 patients. https://rhythm.tums.ac.ir/index.php/jthc/article/view/1313 https://rhythm.tums.ac.ir/index.php/jthc/article/download/1313/940